The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...

Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both before and after surgery for high-risk prostate cancer, significantly ...

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...

Lupin Ltd has received tentative approval from the USFDA for its generic enzalutamide tablets used to treat ...

AstraZeneca (AZN) stock is in focus as the FDA approves a label expansion for its breast cancer therapy Truqap in prostate cancer. Read more here.

Metastatic androgen pathway modulation-naïve or -sensitive prostate cancer was previously referred to as metastatic hormone-sensitive prostate cancer.

MultiValent Biotherapies is developing a peptide-like drug conjugate that hits two validated targets to treat prostate cancer ...

AstraZeneca's drug Truqap in combination with two other medications secured approval for the treatment of a form of advanced prostate cancer by the Food and Drug Administration. Approval was based on ...

According to the company, the US FDA has found Lupin's 40 mg and 80 mg tablets to be bioequivalent to Astellas Pharma's ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery, substantially increased the chances of eliminating cancer and reduced ...

Pass the patch. The US is in the middle of an estrogen patch shortage, with menopausal women struggling to get ahold of ...